TABLE 2

The key phase III studies of cytokine inhibitors licensed for the treatment of rheumatoid arthritis

Target	Generic Name	Key Phase III Study in RA	Reference	Sample Size	Primary Outcome (ACR20)	Duration
						weeks
TNF	Infliximab	ATTRACT	Maini et al., 1999	428	Active: 50–58%	30
TNF	Infliximab	ATTRACT	Maini et al., 1999	428	Placebo: 20%	30
	Adalimumab	ARMADA	Weinblatt et al., 2003	271	Active: 67%	24
	Adalimumab	ARMADA	Weinblatt et al., 2003	271	Placebo: 15%	24
	Etanercept	—	Moreland et al., 1999	234	Active: 59%	24
	Etanercept	—	Moreland et al., 1999	234	Placebo: 11%	24
	Golimumab	GO-FORWARD	Keystone et al., 2009	444	Active + MTX: 56%	14
					Active − MTX: 44%
					Placebo: 33%
	Certolizumab	RAPID-1	Keystone et al., 2008	982	Active: 59–61%	24
	Certolizumab	RAPID-1	Keystone et al., 2008	982	Placebo: 14%	24
IL-6R	Tocilizumab	TOWARD	Genovese et al., 2008	1220	Active: 61%	24
IL-6R	Tocilizumab	TOWARD	Genovese et al., 2008	1220	Placebo: 25%	24
		OPTION	Smolen et al., 2008	623	Active: 48–59%	24
		OPTION	Smolen et al., 2008	623	Placebo: 26%	24
IL-1R	Anakinra	—	Cohen et al., 2004	506	Active: 38%	24
IL-1R	Anakinra	—	Cohen et al., 2004	506	Placebo: 22%	24